The biology of incretin hormones

被引：1748

作者：

Drucker, DJ ^{[1
]}

机构：

[1] Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Med, Toronto, ON M5G 2C4, Canada

来源：

CELL METABOLISM | 2006年 / 3卷 / 03期

关键词：

D O I：

10.1016/j.cmet.2006.01.004

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Gut peptides, exemplified by glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are secreted in a nutrient-dependent manner and stimulate glucose-dependent insulin secretion. Both GIP and GLP-1 also promote beta cell proliferation and inhibit apoptosis, leading to expansion of beta cell mass. GLP-1, but not GIP, controls glycemia via additional actions on glucose sensors, inhibition of gastric emptying, food intake and glucagon secretion. Furthermore, GLP-1, unlike GIP, potently stimulates insulin secretion and reduces blood glucose in human subjects with type 2 diabetes. This article summarizes current concepts of incretin action and highlights the potential therapeutic utility of GLP-1 receptor agonists and dipepticlyl pepticlase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes.

引用

页码：153 / 165

页数：13

共 128 条

[11] Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor
Burcelin, R
Da Costa, A
Drucker, D
Thorens, B
[J]. DIABETES, 2001, 50 (08) : 1720 - 1728
[12] Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
Buse, JB
Henry, RR
Han, J
Kim, DD
Fineman, MS
Baron, AD
[J]. DIABETES CARE, 2004, 27 (11) : 2628 - 2635
[13] Circulating CD26 is negatively associated with inflammation in human and experimental arthritis
Busso, N
Wagtmann, N
Herling, C
Chobaz-Péclat, V
Bischof-Delaloye, A
So, A
Grouzmann, E
[J]. AMERICAN JOURNAL OF PATHOLOGY, 2005, 166 (02) : 433 - 442
[14] Glucagon-like peptide-1 prevents beta cell glucolipotoxicity
Buteau, J
El-Assaad, W
Rhodes, CJ
Rosenberg, L
Joly, E
Prentki, M
[J]. DIABETOLOGIA, 2004, 47 (05) : 806 - 815
[15] Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor
Buteau, J
Foisy, S
Joly, E
Prentki, M
[J]. DIABETES, 2003, 52 (01) : 124 - 132
[16] Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard
Chen, YQE
Drucker, DJ
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (07) : 4108 - 4115
[17] Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
Conarello, SL
Li, ZH
Ronan, J
Roy, RS
Zhu, L
Jiang, GQ
Liu, F
Woods, J
Zycband, E
Moller, DE
Thornberry, NA
Zhang, BB
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (11) : 6825 - 6830
[18] Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons
DAlessio, DA
Vogel, R
Prigeon, R
Laschansky, E
Koerker, D
Eng, J
Ensinck, JW
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (01) : 133 - 138
[19] Therapeutic strategies based on glucagon-like peptide 1
Deacon, CF
[J]. DIABETES, 2004, 53 (09) : 2181 - 2189
[20] Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig
Deacon, CF
Hughes, TE
Holst, JJ
[J]. DIABETES, 1998, 47 (05) : 764 - 769

← 1 2 3 4 5 6 7 8 9 10 →